Published in Gene Therapy Weekly, October 18th, 2001
The patent is one of numerous patents, pending or issued, that Introgen Therapeutics Inc. has licensed exclusively from The University of Texas System based on technology from the University of Texas M.D. Anderson Cancer Center.
Virtually all cancer patients receive DNA-damaging agents...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.